Close to 120 companies across the globe claim to possess the required expertise / Roots Analysis

Author : kevin987
Publish Date : 2021-03-26 05:36:59


Close to 120 companies across the globe claim to possess the required expertise / Roots Analysis

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.

 

To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Key Inclusions

  • A detailed review of the overall landscape of companies offering contract services for the manufacturing of HPAPIs and cytotoxic drugs, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, facility size, type of service(s) offered (clinical manufacturing, commercial manufacturing, analytical testing, scale-up, process development / pre-formulation, formulation development, stability studies, regulatory support and fill / finish and packaging), type of product manufactured (HPAPIs and highly potent finished dosage forms), type of pharmacological molecule (biologics and small molecules), type of highly potent finished dosage form manufactured (capsules, granules, injectables, liquids and tablets), and type of primary packaging used (ampoules, blisters, prefilled syringes, conventional syringes, vials and others).
  • A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, taking into consideration supplier strength (based on company size and its experience in this field) and service strength (based on scale of operation, type of service(s) offered, type of product(s) manufactured, number and location of manufacturing facilities, type of highly potent finished dosage forms manufactured and type of primary packaging used).
  • Elaborate profiles of the key players (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of HPAPIs and cytotoxic drugs, across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various HPAPIs / cytotoxic dugs manufacturing services offered by the company, along with the location of their manufacturing facilities. Further, we have provided the recent developments of the company and an informed future outlook.
  • An analysis of the various partnerships pertaining to the contract manufacturing of HPAPIs and cytotoxic drugs, which have been established since 2014, based on several parameters, such as the year of partnership, type of partnership, type of product, scale of operation, company size, amount invested in acquisitions, most active player and geographical analysis.

The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:

  • Type of Product
  • HPAPIs
  • Highly Potent Finished Dosage Forms

 

  • Company Size
  • Small-sized
  • Mid-sized
  • Large / Very Large

 

  • Scale of Operation
  • Preclinical / Clinical
  • Commercial

 

  • Type of Pharmacological Molecule
  • Small Molecules
  • Biologics

 

  • Type of Highly Potent Finished Dosage Form
  • Injectables
  • Oral Solids
  • Creams
  • Others

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

 

The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”report features the following companies, which we identified to be key players in this domain:

  • AbbVie Contract Manufacturing
  • CARBOGEN AMCIS
  • Catalent
  • Evonik
  • Formosa Laboratories
  • Intas
  • Lonza
  • MabPlex
  • Pfizer CentreOne

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Market Landscape
 

5. Company Competitive Analysis
 

6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles
 

7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles
 

8. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles
 

9. Partnerships and Collaborations
 

10. Recent Expansions
 

11. Capacity Analysis
 

12. Market Sizing and Opportunity Analysis
 

13. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates

 

14. Concluding Remarks

 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]  



Category : general

He suddenly became aware of what a peculiar thought this was. “Am I one or two? If I cannot live with myself, there must

He suddenly became aware of what a peculiar thought this was. “Am I one or two? If I cannot live with myself, there must

- That is why the West is so unhappy. Why America, in particular, is a desperate unhappy nation. Happiness comes to us from social bonds. It is the gift we receive from sociality — one of many. Bu


Pass Dell EMC E20-655 Exam Questions In First Attempt

Pass Dell EMC E20-655 Exam Questions In First Attempt

- CertsLeads enables you to prepare your certification exams, Get most actual and updated exam questions PDF for passing the certifications exam in first attempt


EU BLOCKS shipment of 250,000 AstraZeneca jabs from being exported to Australia

EU BLOCKS shipment of 250,000 AstraZeneca jabs from being exported to Australia

- EU BLOCKS shipment of 250,000 AstraZeneca jabs from being exported to Australia, find out more here


Top 10 Best Tourist Attraction Places In Malaysia

Top 10 Best Tourist Attraction Places In Malaysia

- Malaysia exudes a feeling of dynamism and exceptional personality that brings thousands and hundreds of overseas tourists all-year-round